

## CASE REPORT

## Concomitant Invasive Pneumococcal Disease in a Patient with COVID-19 – A Case Report from the Louisville Epidemiology Study

Clayton J. Patross<sup>1</sup>, PharmD, BCPS; Brian C. Bohn<sup>1</sup>, PharmD; Sarah E. Moore<sup>1</sup>, PharmD; Paul S. Schulz<sup>2</sup>, MD; Matthew Song<sup>1</sup>, PharmD, BCIDP; Ashley M. Wilde<sup>1</sup>, PharmD, BCPS-AQ ID; Julio A. Ramirez<sup>3</sup>, MD; and the Louisville Epidemiology Study Group

<sup>1</sup>Norton Pharmacy Services, Norton Healthcare, Louisville, KY, <sup>2</sup>Norton Infectious Diseases Specialists, Norton Healthcare, Louisville, KY, <sup>3</sup>Division of Infectious Diseases, Department of Medicine, University of Louisville School of Medicine, Louisville, KY

\*clayton.patros@nortonhealthcare.org

### Abstract

A 60-year-old male presented to the Emergency Department (ED) with a one-two day history of confusion, headache, and subjective fever. Because he had met with a contact two days prior to admission who had recently traveled from the Bahamas, a COVID-19 nasopharyngeal (NP) and oropharyngeal (OP) polymerase chain reaction (PCR) test was ordered. He was diagnosed with bacterial meningitis based on presenting neurologic symptoms and the identification of *Streptococcus pneumoniae* from blood cultures. The COVID-19 NP and OP test returned positive, although he never developed shortness of breath, cough, other respiratory symptoms, diarrhea, abdominal pain, nausea, vomiting, or any change in sense of smell or taste. On day three of admission, the patient had improved clinically on intravenous (IV) antibiotics and was discharged home with instructions to self-quarantine. This case demonstrates the possibility of co-infections with COVID-19 and raises the possibility of an association between COVID-19 and patient susceptibility to invasive pneumococcal disease (IPD).

### Introduction

Previous literature has shown associations with both influenza and respiratory syncytial virus activity and the incidence of both IPD and pneumococcal meningitis. [1-5] Currently, no such association or examples have been provided with COVID-19 and IPD. With the rapid progression of COVID-19 prevalence and mortality, the documentation and characterization of potential complications and risks of COVID-19 are needed. This case describes concomitant pneumococcal meningitis in a patient positive for COVID-19 and discusses the potential role that COVID-19 may have in the pathogenesis of IPD and meningitis.

### Case Report

A 60-year-old male presented to emergency department with a one to two day history of confusion, headache, and subjective fever. His past medical history includes hypertension, hyperlipidemia, and arthritis, and has no vaccination history listed in his medical record. The patient's wife described the patient was in his baseline health the night prior to admission, which is alert and oriented times four. On the morning of admission, she noted that the patient was chilled and shaking, and asking for a blanket. At that time, he stopped talking and was noted to be extremely weak, unable to stand up without full assistance. She denied any recent illness, cough, shortness of breath, nausea, vomiting, or diarrhea. The patient's wife did report that the patient recently returned from a trip to Spain. No specifics on the trip were included in the patient's medical record (departure, return, duration, destinations, activities, etc.). The family also reported that the patient had contact with a friend two days prior to admission who had recently traveled from the Bahamas. The person who had traveled to the Bahamas had been back in the United States for about two weeks with no respiratory, gastrointestinal, or other infectious symptoms. No other known sick contacts or possible exposures were noted.

#### Recommended Citation:

Patross, Clayton J.; Bohn, Brian C.; Moore, Sarah E.; Schulz, Paul S.; Song, Matthew; Wilde, Ashley M.; Ramirez, Julio A. and the Louisville Epidemiology Study Group (2020). "Concomitant Invasive Pneumococcal Disease in a Patient with COVID-19 – A Case Report from the Louisville Epidemiology Study," *The University of Louisville Journal of Respiratory Infections*: Vol. 4, Iss. 1, Article 42.

Received Date: April 29, 2020

Accepted Date: May 8, 2020

Published Date: July 6, 2020

Copyright: © 2020 The author(s). This original article is brought to you for free and open access by ThinkIR: The University of Louisville's Institutional Repository. For more information, please contact thinkir@louisville.edu. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Funding Source: The author(s) received no specific funding for this work.

Conflict of Interest: All authors declared no conflict of interest in relation to the main objective of this work.

**Table 1.** Vital Signs

Day of Admission	Temperature (°F)	Heart Rate (bpm)	Respiratory Rate (breaths/min)	Blood Pressure (mm Hg)
Initial	102	115	22	177/108
Day 1	97.5-102	84-115	16-26	150-191/81-109
Day 2	96.7-98.4	76-110	13-26	113-157/70-96
Day 3	97.6-98.3	68-75	16-17	134-153/85-91

**Table 2.** Laboratory Values

Day of Admission	WBC 10 <sup>3</sup> cells/μL	Lymphocyte %	T- Bili mg/dL	ALT U/L	AST U/L	Alk Phos U/L	PCT ng/mL	Lactic Acid mmol/L	CRP mg/dL	ESR mm/hr
Day 1	15.55	4.9	1.1	31	44	61	–	3.8	–	–
Day 2	23.74	2.7	–	–	–	–	6.34	6.3	–	–
Day 3	22.59	3.3	–	–	–	–	–	–	–	–
(Day 7)	9.26	15.2	–	–	–	–	–	–	2.5	31
(Day 14)	6.62	16.5	–	–	–	–	–	–	1.5	34


Initial vital signs were significant for a temperature of 39.1 °C (102.3 °F) and heart rate of 104 bpm (**Table 1**). The physical exam in the ED noted no nuchal rigidity and was unremarkable other than severely altered mental status and non-verbal status. Brudzinski’s or Kernig’s signs were not assessed. Significant labs on admission included an elevated WBC of 15.55 x 10<sup>3</sup> cells/μL, elevated procalcitonin of 6.34 ng/mL, and an elevated lactic acid of 3.8 mmol/L (**Table 2**).

Chest X-ray reported no evidence of cardiopulmonary abnormality. A CT of the head, chest, abdomen and pelvis was obtained. The head CT without contrast demonstrated no mass lesion, hemorrhage or acute artifact. The chest CT without contrast was limited by motion artifact, but did not show any evidence of acute airspace disease or pleural effusion (**Figure 1**). Subsequently, an MRI of the brain with and without contrast was obtained (**Figure 2**). The report noted fluid with restricted diffusion layers dependently in the lateral ventricles without hydrocephalus consistent with ventriculitis. The image was limited by motion to assess for corresponding enhancement or leptomeningeal enhancement. Due to the noted travel history and contact, the patient was tested for COVID-19 disease by a combined nasopharyngeal/oropharyngeal swab sent for PCR and the patient was placed in appropriate isolation. Unfortunately, a lumbar puncture was not obtained due to COVID-19 isolation. Treatment was started with ampicillin 2 g IV q4 hours, ceftriaxone 2 g IV q12 hours, vancomycin 1750 mg IV q12 hours, and dexamethasone 10 mg IV q6 hours for suspected acute bacterial meningitis.


The patient significantly improved with antibiotics. Two of two blood culture sets resulted on day two of admission with gram-positive cocci in pairs and chains. *Streptococcus pneumoniae* was identified by the Verigene system (Nanosphere Inc., Northbrook, IL, USA). Susceptibilities identified a multidrug resistant *Streptococcus pneumoniae* on day three of admission. The *S. pneumoniae* MIC was 2 μg/mL to penicillin and 2 μg/mL to ceftriaxone. On the third day of admission, the SARS-CoV-2 PCR resulted positive. The patient remained without evidence of symptoms related to COVID-19 disease (respiratory, gastrointestinal) throughout his hospital admission. The patient received IV vancomycin after discharge for the duration of their meningitis therapy.

## Discussion


The pathogenesis of pneumococcal meningitis consists of bacterial colonization of mucous membranes, translocation into the bloodstream, survival in the bloodstream, and eventual entry and replication in the central nervous system. [6,7] Before *S. pneumoniae* can colonize, it first needs to adhere to mucosal surfaces, which it accomplishes through three different types of receptors: the platelet-activating factor receptor, laminin receptors, and the polymeric immunoglobulin receptor. After initial adherence, colonization is promoted by the evasion of secretory immune globulin A (IgA). Pathogen secretion of proteases helps to inactivate IgA. Although it widely varies from study to study, *S. pneumoniae* colonization of the nasopharynx is generally considered common even in healthy children and adults with its incidence reported anywhere from 8.6% - 33.2%. [8,9] After sufficient colonization of the pathogen, invasion of tissues and translocation into the bloodstream can occur. Although this occurs significantly less often than colonization, there are many factors that can facilitate translocation into the bloodstream including environmental factors, host factors, and pathogen virulence.



**Figure 1.** Chest CT: Computed tomography image of the chest with no evidence or findings of cardiopulmonary abnormalities.



**Figure 2.** Brain MRI: Magnetic resonance image of the brain showing bilateral 6 mm x 4 mm collections layering in the posterior horns of the lateral ventricles (red arrows). The differential diagnosis includes ventriculitis versus mild subarachnoid hemorrhage.



**Figure 3.** Brain MRI Gradient ECHO: Magnetic resonance image with normal signal suggesting low likelihood for subarachnoid hemorrhage.

The association between respiratory viruses and increased incidence of IPD and pneumococcal meningitis has been documented, which is a common example of environmental factors influencing pneumococcal disease. [10-13] Possible mechanisms of increased susceptibility to IPD include the respiratory viruses' ability to impair the host's innate immune system by recruiting inflammatory mediators and damaging mucosal and epithelial tissue. [11-14] Damage to these tissues and the resulting mucosal impairment and increased permeability of epithelia can facilitate bacterial pathogen adherence and promote translocation. This has been commonly used to explain the association between both influenza and RSV activity and the increased incidence of IPD and meningitis. Specific mechanisms have been described, including a synergistic activation of interferons from influenza virus and pneumococcal coinfection [12] as well as the stimulation of the platelet-activating factor receptor in the host defense against *S. pneumoniae* following influenza infections [13].

The primary route of entry for SARS-CoV-2 is thought to be through the nasopharynx, which can eventually progress into the airways and lower respiratory tract. [15] Similar to other viral pathogens, COVID-19 has been shown to recruit inflammatory cytokines including IL-1, IL-6, IL-7, IL-8, IL-9, IL-10, IFN- $\gamma$ , and TNF- $\alpha$  among others. [16,17] These pro-inflammatory mediators that have been found in patients with COVID-19 are also known to cause tissue damage, and may provide a link to COVID-19 and increased host susceptibility to IPD.

This case provides an example of a patient that was either colonized or infected with SARS-CoV-2, and that developed concomitant pneumococcal meningitis. Interestingly, this patient did not demonstrate any signs or symptoms consistent with pneumonia from either *S. pneumoniae* or COVID-19. Although cause cannot be determined, this case demonstrates the ability of COVID-19 to co-habit with bacterial pathogens, and raises the question of whether COVID-19 can be involved in the pathogenesis of and susceptibility to IPD similar to what has been described with other respiratory viruses.

Another key point is the importance of epidemiology in screening and diagnosis of patients during an outbreak in addition to symptoms and radiographic evidence of disease. This patient would likely not have been screened without the mention of a possible sick contact and travel history, which may have resulted in further spread of COVID-19. Patients with known or high-risk exposure during an outbreak (such as sick contacts or travel history) should be tested for COVID-19 in order to decrease spread from persons with asymptomatic carriage or subclinical presentation.

## References

1. Jansen AG, Sanders EA, VAN DER Ende A, VAN Loon AM, Hoes AW, Hak E. Invasive pneumococcal and meningococcal disease: association with influenza virus and respiratory syncytial virus activity? *Epidemiol Infect.* 2008 Nov;136(11):1448–54. <https://doi.org/10.1017/S0950268807000271> PMID:18211724
2. Zhou H, Haber M, Ray S, Farley MM, Panozzo CA, Klugman KP. Invasive pneumococcal pneumonia and respiratory virus co-infections. *Emerg Infect Dis.* 2012 Feb;18(2):294–7. <https://doi.org/10.3201/eid1802.102025> PMID:22305270
3. Ciruela P, Broner S, Izquierdo C, Hernández S, Muñoz-Almagro C, Pallarés R, et al.; Working Group of Invasive Pneumococcal Disease of Catalonia. Invasive pneumococcal disease rates linked to meteorological factors and respiratory virus circulation (Catalonia, 2006–2012). *BMC Public Health.* 2016 May;16(1):400–7. <https://doi.org/10.1186/s12889-016-3061-6> PMID:27178436
4. Li Y, Peterson ME, Campbell H, Nair H. Association of seasonal viral acute respiratory infection with pneumococcal disease: a systematic review of population-based studies. *BMJ Open.* 2018 Apr 1;8(4):e019743. <https://doi.org/10.1136/bmjopen-2017-019743> PMID:29680810
5. Hendriks W, Boshuizen H, Dekkers A, Knol M, Donker GA, van der Ende A, et al. Temporal cross-correlation between influenza-like illnesses and invasive pneumococcal disease in The Netherlands. *Influenza Other Respir Viruses.* 2017 Mar;11(2):130–7. <https://doi.org/10.1111/irv.12442> PMID:27943624
6. McGill F, Heyderman RS, Panagiotou S, Tunkel AR, Solomon T. Acute bacterial meningitis in adults. *Lancet.* 2016 Dec;388(10063):3036–47. [https://doi.org/10.1016/S0140-6736\(16\)30654-7](https://doi.org/10.1016/S0140-6736(16)30654-7) PMID:27265346
7. van de Beek D, Brouwer M, Hasbun R, Koedel U, Whitney CG, Wijdicks E. Community-acquired bacterial meningitis. *Nat Rev Dis Primers.* 2016 Nov;2(1):16074. <https://doi.org/10.1038/nrdp.2016.74> PMID:27808261
8. Marchisio P, Esposito S, Schito G, et al. Nasopharyngeal carriage of *Streptococcus pneumoniae* in healthy children: implications for the use of heptavalent pneumococcal conjugate vaccine. *Emerg Infect Dis.* 2002;8(5):479–484. <https://doi.org/10.3201/eid0805.010235> PMID:11996682
9. Reisman J, Rudolph K, Bruden D, Hurlburt D, Bruce M, Hennessy T. Risk factors for pneumococcal colonization of the nasopharynx in Alaska native adults and children. *J Ped Infect Dis Soc.* 2014;3(2):104–111. <https://doi.org/10.1093/jpids/pit069> PMID:26625363
10. Swartz MN. Bacterial meningitis—a view of the past 90 years. *N Engl J Med.* 2004 Oct;351(18):1826–8. <https://doi.org/10.1056/NEJMp048246> PMID:15509815
11. Talbot TR, Poehling KA, Hartert TV, Arbogast PG, Halasa NB, Edwards KM, et al. Seasonality of invasive pneumococcal disease: temporal relation to documented influenza and respiratory syncytial viral circulation. *Am J Med.* 2005 Mar;118(3):285–91. <https://doi.org/10.1016/j.amjmed.2004.09.016> PMID:15745727
12. Nakamura S, Davis KM, Weiser JN. Synergistic stimulation of type I interferons during influenza virus coinfection promotes *Streptococcus pneumoniae* colonization in mice. *J Clin Invest.* 2011 Sep;121(9):3657–65. <https://doi.org/10.1172/JCI157762> PMID:21841308
13. van der Sluijs KF, van Elden LJ, Nijhuis M, Schuurman R, Florquin S, Shimizu T, et al. Involvement of the platelet-activating factor receptor in host defense against *Streptococcus pneumoniae* during postinfluenza pneumonia. *Am J Physiol Lung Cell Mol Physiol.* 2006 Jan;290(1):L194–9. <https://doi.org/10.1152/ajplung.00050.2005> PMID:16100290
14. McCullers JA. Insights into the interaction between influenza virus and pneumococcus. *Clin Microbiol Rev.* 2006 Jul;19(3):571–82. <https://doi.org/10.1128/CMR.00058-05> PMID:16847087
15. Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al. Virology, epidemiology, pathogenesis, and control of COVID-19. *Viruses.* 2020 Mar;12(4):372–88. <https://doi.org/10.3390/v12040372> PMID:32230900
16. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020 Feb;395(10223):497–506. [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5) PMID:31986264
17. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. *J Pharm Anal.* 2020 Apr;10(2):102–8. <https://doi.org/10.1016/j.jpha.2020.03.001> PMID:32282863